Arrowhead Pharmaceuticals (ARWR) Notes Payables (2010 - 2018)

Arrowhead Pharmaceuticals (ARWR) has 9 years of Notes Payables data on file, last reported at $223820.0 in Q3 2018.

• Quarterly Notes Payables rose 7.34% year-over-year to $223820.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $223820.0 (up 7.34% YoY) and the FY2018 annual result came in at $223820.0, up 7.34% from the prior year.
• Notes Payables grew to $223820.0 in Q3 2018, from $219889.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $4.9 million in Q1 2014 to a low of $50000.0 in Q2 2014.
• A 5-year average of $1.1 million and a median of $223820.0 in 2018 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2014 — Notes Payables tumbled 97.86% — and 2015, when it surged 3348.94%.
• Tracing ARWR's Notes Payables over 5 years: stood at $1.8 million in 2014, then decreased by 25.99% to $1.3 million in 2015, then slumped by 85.08% to $197713.0 in 2016, then rose by 7.34% to $212233.0 in 2017, then grew by 5.46% to $223820.0 in 2018.
• The last three Notes Payables figures came in at $223820.0 (Q3 2018), $219889.0 (Q2 2018), and $216027.0 (Q1 2018), per Business Quant data.